Skip to Content

Regeneron Pharmaceuticals Inc REGN

Morningstar Rating
$1,053.14 +8.75 (0.84%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Regeneron's Solid Immunology Drug Dupixent and Growing Oncology Pipeline Support a Narrow Moat

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat. Lead drug Eylea has global sales around $9 billion annually and is approved for wet age-related macular degeneration and other eye-related indications. The drug remains well positioned, as its high-dose formulation should allow it to continue to hold strong market share against biosimilars and Roche's new branded drug, Vabysmo.

Price vs Fair Value

REGN is trading at a 446% premium.
Price
$1,053.14
Fair Value
$359.00
Uncertainty
Medium
1-Star Price
$2,141.50
5-Star Price
$593.00
Economic Moat
Fmqqq
Capital Allocation
Wtvwvwlh

Bulls Say, Bears Say

Bulls

Eylea has become the leading franchise in wet AMD and other ophthalmology markets because of its similar efficacy and more convenient dosing regimen compared with Lucentis and Avastin.

Bears

Regeneron's Eylea is competing with Roche and Novartis in the ophthalmology market, and it could be vulnerable to biosimilars beginning in 2024 and Medicare negotiations in 2028.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if REGN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1,044.39
Day Range
$1,041.251,059.80
52-Week Range
$684.811,059.80
Bid/Ask
$1,053.66 / $1,075.00
Market Cap
$116.04 Bil
Volume/Avg
1.3 Mil / 441,869

Key Statistics

Price/Earnings (Normalized)
24.36
Price/Sales
9.16
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.22%

Company Profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
13,450

Competitors

Valuation

Metric
REGN
AMGN
NVS
Price/Earnings (Normalized)
24.3616.5415.25
Price/Book Value
4.3032.895.41
Price/Sales
9.165.614.38
Price/Cash Flow
25.9119.4514.52
Price/Earnings
REGN
AMGN
NVS

Financial Strength

Metric
REGN
AMGN
NVS
Quick Ratio
4.400.840.61
Current Ratio
5.271.420.90
Interest Coverage
49.942.3811.32
Quick Ratio
REGN
AMGN
NVS

Profitability

Metric
REGN
AMGN
NVS
Return on Assets (Normalized)
15.57%10.91%13.39%
Return on Equity (Normalized)
19.91%161.62%31.09%
Return on Invested Capital (Normalized)
16.29%18.59%19.67%
Return on Assets
REGN
AMGN
NVS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FncfsktbkZjgz$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
XnvmmdqpXjfhjdg$121.0 Bil
Moderna Inc
MRNA
LlyftsswZwmh$51.1 Bil
argenx SE ADR
ARGX
LpcmrlgZpg$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
XzzljmrwDszdj$21.0 Bil
BioNTech SE ADR
BNTX
SmbgwcbgTnjr$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
VgykxgkMpswhbb$15.9 Bil
United Therapeutics Corp
UTHR
FyhwhfhvQpqz$14.0 Bil
Incyte Corp
INCY
CwthttwxxYxqbdd$12.5 Bil

Sponsor Center